Highlights

  • IperionX shares fell 8.99% on 13 March 2026, following the release of its H1FY26 results.
  • Loss for the period reached USD 34.76 million in H1 FY26, compared with USD 16.24 million in H1 FY25.
  • Corporate and administrative expenses were the largest cost, totaling USD 16.21 million in H1 FY26, compared with USD 3.28 million in H1 FY25
  • Net cash used in investing activities was USD 16.38 million in H1 FY26, compared with USD 10.97 million in H1 FY25
  • Cash and cash equivalents stood at USD 65.83 million as of 31 December 2025, compared with USD 77.13 million as of 31 December 2024.

IperionX Ltd (ASX:IPX) shares dropped 8.99% to AUD 5.56 in the afternoon session on 13 March 2026, placing the stock among notable decliners on the ASX. The stock has also declined 14.33% over the past five days.

Today’s decline follows the company’s half-year financial results released on 12 March, which reported a wider loss for the period.

Today’s pullback also coincided with broader weakness in the resources space, with the S&P/ASX 200 Materials Index declining 1.23%, adding pressure to materials-related stocks. Despite the recent decline, IperionX shares remain significantly higher, +74.29% over the past 12 months, reflecting strong longer-term market interest in the company’s titanium and critical minerals strategy.

Half-Year Results Show Wider Loss

For the six months ended 31 December 2025 (H1 FY26), IperionX reported a loss for the period of USD 34.76 million, compared with a loss of USD 16.24 million in the six months ended 31 December 2024 (H1 FY25). The result represents a notable increase in losses compared with the prior corresponding period.

The company recorded research and development costs of USD 10.79 million in H1 FY26, compared with USD 6.81 million in H1 FY25, reflecting continued investment in technological development. Exploration and evaluation expenses also rose, reaching USD 3.30 million in H1 FY26, compared with USD 1.39 million in H1 FY25.

Corporate and administrative expenses totalled USD 16.21 million in H1 FY26, compared with USD 3.28 million in H1 FY25. In addition, business development expenses amounted to USD 1.65 million in H1 FY26, compared with USD 2.15 million in H1 FY25, while share-based payment expenses were USD 4.67 million in H1 FY26, compared with USD 6.91 million in H1 FY25.

After accounting for these items, the company reported a loss before income tax of USD 34.77 million in H1 FY26, compared with USD 16.24 million in H1 FY25.

Cash Flow and Liquidity Position

In terms of cash flow, IperionX recorded net cash used in operating activities of USD 16.71 million in H1 FY26, compared with USD 11.48 million used in operating activities in H1 FY25. Net cash used in investing activities totaled USD 16.38 million in H1 FY26, compared with USD 10.97 million in H1 FY25.

Financing activities provided net cash inflows of USD 43.92 million in H1 FY26, compared with USD 6.21 million in H1 FY25. As a result, the company reported a net increase in cash and cash equivalents of USD 10.84 million during H1 FY26, compared with a net increase of USD 45.48 million in H1 FY25.

At the end of the period, cash and cash equivalents stood at USD 65.83 million as of 31 December 2025, compared with USD 77.13 million as of 31 December 2024.

What This Means for Investors?

The market reaction to IperionX’s results reflects investor response to the larger loss reported for the half-year period, alongside continued spending across research, development, and operational activities. Combined with broader weakness in the materials sector, the results contributed to today’s decline in the company’s share price. Investors are likely to continue monitoring the company’s financial performance and cash position as it progresses its development initiatives in the titanium and critical minerals space.

Frequently Asked Questions (FAQs)

  1. Why did IperionX (ASX:IPX) shares fall on 13 March 2026?
    IperionX shares declined 8.99% to AUD 5.56 on 13 March 2026 after the company released its half-year results for the six months ended 31 December 2025 (H1 FY26), which showed a wider loss compared to the prior corresponding period.
  2. What loss did IperionX report for H1 FY26?
    For the six months ended 31 December 2025 (H1 FY26), IperionX reported a loss of USD 34.76 million, compared with a loss of USD 16.24 million for the six months ended 31 December 2024 (H1 FY25).
  3. What was IperionX’s cash position at the end of the half-year period?
    As of 31 December 2025, IperionX reported cash and cash equivalents of USD 65.83 million, compared with USD 77.13 million as of 31 December 2024.